Reports in category Initiating Coverage
| S.J.S. Enterprises Ltd (Ashish Kacholia Portfolio Stock) has clean & clear visible growth triggers. Buy for TP of Rs 593 (+33%): SMIFS | |
| Company: | S.J.S. Enterprises |
| Brokerage: | SMIFS |
| Date of report: | January 30, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 33% |
| Summary: | We are of the opinion that SJS at ease will be able to achieve PAT growth @18% CAGR FY22-FY25e with sustainable margin of about 25%+ level. Over & above, the team is aggressively hunting for inorganic acquisition, which can add a new wing in either technology, futuristic products, markets and/or customers |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | S.J.S. Enterprises, SMIFS |
| KIMS is steadily building its empire by conquering and ruling. Buy for target price of Rs 1682 (18% upside) | |
| Company: | KIMS, Krishna Institute Of Medical Sciences |
| Brokerage: | SMIFS |
| Date of report: | January 23, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 18% |
| Summary: | Currently, the stock is trading at comforting valuation on FY25E EV/EBITDA of 15x. We value the stock at 20x (in line with its historical average) due to capacity and geographical expansion, improved margins and robust revenue growth, thereby, arrive at target price of Rs 1,682 per share which offers upside of 18% from current valuations. Therefore, we assign BUY rating on the stock. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Krishna Institute Of Medical Sciences |
| Supreme Petrochem has very strong business model. Buy for target price of Rs 561 (51% upside): SMIFS | |
| Company: | Supreme Petrochem |
| Brokerage: | SMIFS |
| Date of report: | January 19, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 51% |
| Summary: | Supreme Petrochem (SPL) has very strong business model in Polystyrene (PS) & Expandable Polystyrene (EPS) along with its downstream derivatives like XPS & SPC. The company is expanding its capacity in all business segments viewing the growth opportunities available post closure of business of its nearest competitor in India, increasing demand growth & strong balance sheet to fund capital expenditure. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | SMIFS, Supreme Petrochem |
| Garden Reach Shipbuilders & Engineers (Stock In Ramesh Damani Portfolio) is a buy for target price of Rs 630 (36% gain): ICICI Direct | |
| Company: | Garden Reach Shipbuilders & Engineers, GRSE |
| Brokerage: | ICICI-Direct |
| Date of report: | January 11, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 36% |
| Summary: | Garden Reach Shipbuilders & Engineers (GRSE), one of India’s leading defence public sector undertaking shipyards, primarily caters to the shipbuilding requirements of the Indian Navy and the Indian Coast Guard |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Garden Reach Shipbuilders & Engineers, ICICI-Direct |
| Transformers and Rectifiers India is firing on all cylinders. Buy for Target Price of Rs 86 (35% upside): ICICI Direct | |
| Company: | Transformers and Rectifiers India |
| Brokerage: | ICICI-Direct |
| Date of report: | January 10, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 35% |
| Summary: | After many years of stagnant performance, growth prospects are looking bright across all parameters. Revenue CAGR of 20% in FY2224E coupled with margins hitting 10.8% in FY24E will enable TRIL to post its best ever profitability performance. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | ICICI Securities, Nano Nivesh, Transformers and Rectifiers India |
| Dolly Khanna is invested in Nitin Spinners. ICICI Direct has recommended a buy for the target price of Rs 290 (41% upside) | |
| Company: | Nitin Spinners |
| Brokerage: | ICICI-Direct |
| Date of report: | January 5, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 41% |
| Summary: | Consistent improvement in financial performance of NSL in spite of cyclical nature of textile industry signifies NSL’s ability of optimum asset utilisation leading to sustainable profit growth. In line with its superior fundamental performance, the stock price has grown at 15% CAGR over last five years |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Nano Nivesh, Nitin Spinners |
| CanFin Homes is in sweet spot. Buy for target price of Rs 625: ICICI Direct | |
| Company: | Can Fin Homes |
| Brokerage: | ICICI-Direct |
| Date of report: | January 2, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 17% |
| Summary: | Consistent business growth with focus on efficient operations coupled with relatively lower cost and strong underwriting to benefit earnings and return ratios |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Can Fin Homes, ICICI-Direct |
| Buy Gujarat Themis Biosyn for target price of Rs 909: HDFC Securities | |
| Company: | Gujarat Themis Biosyn |
| Brokerage: | HDFC Sec |
| Date of report: | January 2, 2023 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 17% |
| Summary: | Prior to FY20, company was engaged in contract manufacturing of Rifamycin S for Lupin. During FY20, management decided to change business model from contract manufacturing to manufacturing and sales model; as a result the company’s operating profitability has significantly improved. Company had reported robust numbers over FY20-22 |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Gujarat Themis Biosyn, HDFC Sec |
| Right time to check-in Chalet Hotels. Buy for target price of Rs 455 (37% Upside): PL | |
| Company: | Chalet Hotels |
| Brokerage: | Prabhudas Lilladher |
| Date of report: | December 27, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 37% |
| Summary: | We initiate coverage on Chalet Hotels Ltd (Chalet) with a ‘BUY’ rating, as it is a play on expected recovery in business travel complemented by an exposure to annuity business (18% share by FY25E) that acts as a hedge to deeply cyclical hospitality industry. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Chalet Hotels, Prabhudas Lilladher |
| Indoco Remedies is an attractive investment proposition. Buy for target price of Rs 469 (24% upside): SMIFS | |
| Company: | indoco remedies |
| Brokerage: | SMIFS |
| Date of report: | December 23, 2022 |
| Type of Report: | |
| Recommendation: | Buy |
| Upside Potential: | 24% |
| Summary: | Strong business fundamentals such as diversified segments mix and strong product portfolio along with high return ratios make Indoco an attractive investment proposition |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | indoco remedies, SMIFS |